Malcolm Spicer, Managing Editor – US
Latest From Malcolm Spicer
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.
Synthetics are necessary for drugs containing cannabinoids because the active ingredient must be consistent from dose to dose. Cannabinoids extracted from hemp vary from plant to plant and more widely from crop to crop, but consistency should matter for cannabinoids used as dietary ingredients, says BioMedican president Dennis O’Neill.
Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.
Executives say Bausch + Lomb spin-out preparations will be completed by the end of Q3. When asked, they elaborated on Carl Icahn’s acquisition of 27.8m shares, for a 7.8% stake, and expansion of the firm’s board by two seats for Icahn’s representatives.
"Now it's up to us to look where can we accelerate our portfolio, in which areas and where can we grow the most and deliver good value for our customers,” says CEO Andreas Fibig.
Jennifer Montgomery, IFF’s probiotics marketing manager for the Americas, responds to HBW Insight questions about the firm’s plans to deliver probiotics ingredients and technologies following the recent closing of its acquisition of DuPont Nutrition & Biosciences through a merger agreement.